Ramucirumab plus FOLFIRI or irinotecan as second-line therapy in advanced or metastatic gastric or gastroesophageal junction adenocarcinoma

Guardat en:
Dades bibliogràfiques
Publicat a:J Gastrointest Oncol
Autors principals: Schlintl, Verena, Huemer, Florian, Greil, Richard, Weiss, Lukas
Format: Artigo
Idioma:Inglês
Publicat: AME Publishing Company 2021
Matèries:
Letter to the Editor
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107630/
https://ncbi.nlm.nih.gov/pubmed/34012679
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo-20-230
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars